The antiapoptotic protein BCL2 is another AML oncogene, a predictor of AML survival and chemoresistance, and the target of venetoclax, one of the most efficacious novel therapies for AML/MDS in combination with azacytidine (Campos et al. 1993; Lagadinou et al. 2013; DiNardo et al. 2020; Wei et al. 2020). The gene discussed is BCL2; the disease is myelodysplastic syndrome.